CTQ.AX down 27% intraday on ASX 10 Feb 2026: top loser and outlook

Careteq Limited (CTQ.AX stock) plunged 27.27% intraday to A$0.008 on the ASX on 10 Feb 2026, making it one of the session’s top losers. Trade volume surged to 4,306,902 shares versus an average of 289,823, indicating heavy selling against thin liquidity. Intraday range was A$0.008–0.011, and the sell-off follows limited company news but elevated market sensitivity in small-cap health-tech names. This intraday move is a reminder of volatility in low-price ASX microcaps and why position sizing matters.

CTQ.AX stock intraday drop and volume

Careteq Limited (CTQ.AX) fell 27.27% intraday to A$0.008 on 10 Feb 2026 on the ASX. Volume hit 4,306,902 shares, almost 15× the average of 289,823, showing forced or reactive selling. The intraday high was A$0.011 and the low matched the close at A$0.008, underscoring a liquidity-driven decline rather than a measured re-pricing.

CTQ.AX stock: valuation and core financials

Careteq’s market cap is about A$1,896,950 with 237,118,720 shares outstanding and EPS of -0.01. Reported ratios include PE -0.80 and PB 0.94, while price-to-sales is 0.25. The company shows revenue per share 0.0426 and free cash flow per share -0.00450, reflecting early-stage cash burn and modest revenue scale. Debt to equity sits at 1.56, and the current ratio is 1.03, so solvency is tight relative to peers.

Meyka AI grade and technical read for CTQ.AX stock

Meyka AI rates CTQ.AX with a score out of 100: 67.29 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. Technicals show RSI 54.48, ADX 28.20 (strong trend), and MFI 82.20 (overbought earlier), suggesting short-term momentum swings. Investors should weigh the Meyka grade against microcap volatility and limited analyst coverage.

Drivers, news links and sector context

There is no fresh company announcement tied to today’s sell-off; the healthcare small-cap group has seen sporadic re-pricing. Careteq’s next earnings date is 02 Mar 2026, which could amplify moves. Sector peers in Healthcare show mixed performance; small-cap medtech names can gap on volume or peer comparisons. For market context see a recent ASX competitor comparison on Investing.com source.

CTQ.AX stock forecast, price targets and trading strategy

Meyka AI’s forecast model projects a short-term monthly level of A$0.010 and a 12‑month median of about A$0.010. Versus today’s A$0.008, that implies an upside of roughly 24.0% to the 12‑month median. Given liquidity and debt metrics, downside scenarios to A$0.005 (about -37.5%) are plausible if selling continues. For traders we suggest small position sizes, tight stops, and watching the A$0.016 year high as a technical resistance level on any rebound.

Final Thoughts

CTQ.AX stock is a high‑volatility microcap on the ASX and the 27.27% intraday fall to A$0.008 on 10 Feb 2026 underscores that risk. Key facts: market cap is about A$1,896,950, volume spiked to 4,306,902, EPS is -0.01, and debt-to-equity is 1.56. Meyka AI’s forecast model projects a near-term level of A$0.010, implying approximately 24.0% upside from the current price, but forecasts are model-based and not guarantees. Our read: the stock mixes modest revenue per share with negative cash flow and above-average leverage, so recovery depends on operational improvements or fresh capital. Traders seeking exposure should treat CTQ.AX stock as speculative, size positions carefully, set firm stop-losses and monitor the 02 Mar 2026 earnings date. Meyka AI provides this as AI-powered market analysis and not personal financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.